磷霉素对含 blaKPC 肺炎克雷伯菌分离株的体外活性研究，包括那些对替加环素和/或多粘菌素不敏感的分离株。
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
机构信息
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
出版信息
Antimicrob Agents Chemother. 2010 Jan;54(1):526-9. doi: 10.1128/AAC.01235-09. Epub 2009 Nov 9.
Abstract
In vitro activity of fosfomycin was evaluated against 68 bla(KPC)-possessing Klebsiella pneumoniae (KpKPC) isolates, including 23 tigecycline- and/or colistin-nonsusceptible strains. By agar dilution, 93% of the overall KpKPC were susceptible (MIC(50/90) of 16/64 microg/ml, respectively). The subgroup of 23 tigecycline- and/or colistin-nonsusceptible strains showed susceptibility rates of 87% (MIC(50/90) of 32/128 microg/ml, respectively). Notably, 5 out of 6 extremely drug-resistant (tigecycline and colistin nonsusceptible) KpKPC were susceptible to fosfomycin. Compared to agar dilution, disk diffusion was more accurate than Etest.
摘要
体外研究评估了磷霉素对 68 株携带 bla(KPC)的肺炎克雷伯菌（KpKPC）的活性，包括 23 株对替加环素和/或黏菌素不敏感的菌株。琼脂稀释法的结果显示，总体上 93%的 KpKPC 对磷霉素敏感（MIC50/90 分别为 16/64μg/ml）。23 株对替加环素和/或黏菌素不敏感的菌株的敏感率为 87%（MIC50/90 分别为 32/128μg/ml）。值得注意的是，6 株极度耐药（对替加环素和黏菌素不敏感）的 KpKPC 中有 5 株对磷霉素敏感。与琼脂稀释法相比，纸片扩散法比 Etest 更准确。
相似文献
1
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.磷霉素对含 blaKPC 肺炎克雷伯菌分离株的体外活性研究，包括那些对替加环素和/或多粘菌素不敏感的分离株。
Antimicrob Agents Chemother. 2010 Jan;54(1):526-9. doi: 10.1128/AAC.01235-09. Epub 2009 Nov 9.
2
In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.体外研究磷霉素联合亚胺培南、美罗培南、黏菌素和替加环素对产 OXA-48 阳性肺炎克雷伯菌的活性。
Diagn Microbiol Infect Dis. 2013 Jul;76(3):335-8. doi: 10.1016/j.diagmicrobio.2013.04.004. Epub 2013 May 29.
3
Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.比较黏菌素、磷霉素和替加环素对产超广谱β-内酰胺酶肺炎克雷伯菌分离株或碳青霉烯类耐药株的协同作用。
J Microbiol Immunol Infect. 2017 Dec;50(6):931-939. doi: 10.1016/j.jmii.2016.12.008. Epub 2017 Jul 6.
4
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.体外研究新型氨基糖苷类药物普拉佐米星单独及与黏菌素、美罗培南、磷霉素或替加环素联合对产碳青霉烯酶肠杆菌科菌株的活性。
Int J Antimicrob Agents. 2015 Dec;46(6):616-21. doi: 10.1016/j.ijantimicag.2015.07.021. Epub 2015 Sep 9.
5
The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients.定植压力在重症患者中耐黏菌素或替加环素的产KPC肺炎克雷伯菌传播中的作用
Infection. 2014 Oct;42(5):883-90. doi: 10.1007/s15010-014-0653-x. Epub 2014 Jul 10.
6
Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.替加环素单独及联合黏菌素和美罗培南对产碳青霉烯酶肠杆菌科细菌（KPC）菌株的时间杀菌试验研究。
Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031. Epub 2011 Jan 13.
7
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.通过体外时间杀菌实验评估用于产VIM和NDM的肺炎克雷伯菌的双联和三联抗生素组合。
Antimicrob Agents Chemother. 2014;58(3):1757-62. doi: 10.1128/AAC.00741-13. Epub 2014 Jan 6.
8
Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates.评价体外方法检测替加环素联合用药对产碳青霉烯酶肺炎克雷伯菌分离株的效果。
J Glob Antimicrob Resist. 2020 Mar;20:98-104. doi: 10.1016/j.jgar.2019.07.028. Epub 2019 Aug 6.
9
Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods.采用多种商业方法对产KPC肺炎克雷伯菌进行磷霉素药敏试验时出现的差异。
Diagn Microbiol Infect Dis. 2019 Jan;93(1):74-76. doi: 10.1016/j.diagmicrobio.2018.07.014. Epub 2018 Jul 31.
10
In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.黏菌素联合其他抗菌药物对耐黏菌素产KPC肺炎克雷伯菌血流分离株的体外活性及抗生素后效应
J Antimicrob Chemother. 2014 Jul;69(7):1856-65. doi: 10.1093/jac/dku065. Epub 2014 Mar 19.
引用本文的文献
1
Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant .头孢他啶-阿维巴坦联合不同抗菌药物对碳青霉烯类耐药. 的影响。
Microbiol Spectr. 2024 Jun 4;12(6):e0010724. doi: 10.1128/spectrum.00107-24. Epub 2024 May 7.
2
[UhpT mutation along with the presence of genes in the genome probably contributes to inherent fosfomycin resistance of ].超磷酸转运蛋白（UhpT）突变以及基因组中基因的存在可能导致[]对磷霉素具有内在抗性。
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Jul 20;43(7):1110-1115. doi: 10.12122/j.issn.1673-4254.2023.07.07.
3
Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC CARBA NP and Xpert™Carba-R Assay.通过比较评估RAPIDEC CARBA NP和Xpert™Carba-R检测法检测耐碳青霉烯类肠杆菌科细菌中的碳青霉烯耐药性
Infect Drug Resist. 2023 Feb 22;16:1123-1131. doi: 10.2147/IDR.S393739. eCollection 2023.
4
Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant .与耐碳青霉烯类药物中磷霉素耐药相关的转运体基因和fosA
Front Microbiol. 2022 Jan 31;13:816806. doi: 10.3389/fmicb.2022.816806. eCollection 2022.
5
The Genomic Characterization of KPC-Producing from the ICU of a Teaching Hospital in Shanghai, China.中国上海一家教学医院重症监护病房产KPC菌株的基因组特征分析
Infect Drug Resist. 2022 Jan 11;15:69-81. doi: 10.2147/IDR.S343673. eCollection 2022.
6
Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers.与间歇输注相比，持续输注磷霉素后的临床药代动力学：一项在健康志愿者中的随机交叉研究。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01375-20.
7
Fosfomycin, Applying Known Methods and Remedies to A New Era.磷霉素，将已知方法和疗法应用于新时代。
Diseases. 2020 Aug 7;8(3):31. doi: 10.3390/diseases8030031.
8
Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting.多剂量口服磷霉素用于门诊治疗复杂性尿路感染
Open Forum Infect Dis. 2020 Jan 29;7(2):ofaa034. doi: 10.1093/ofid/ofaa034. eCollection 2020 Feb.
9
Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.医院获得性细菌性肺炎的流行病学、治疗与预防
J Clin Med. 2020 Jan 19;9(1):275. doi: 10.3390/jcm9010275.
10
The Role of in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.在多物种产碳青霉烯酶肺炎克雷伯菌临床分离株的磷霉素药敏试验挑战中 的作用。
J Clin Microbiol. 2019 Sep 24;57(10). doi: 10.1128/JCM.00634-19. Print 2019 Oct.
本文引用的文献
1
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.ACHN-490，一种对多重耐药肺炎克雷伯菌分离株具有强大体外活性的新糖苷。
Antimicrob Agents Chemother. 2009 Oct;53(10):4504-7. doi: 10.1128/AAC.00556-09.
2
Susceptibility of urinary tract bacteria to fosfomycin.尿路细菌对磷霉素的敏感性。
Antimicrob Agents Chemother. 2009 Oct;53(10):4508-10. doi: 10.1128/AAC.00721-09. Epub 2009 Aug 17.
3
High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.患有细菌性足部感染的糖尿病患者骨组织和外周软组织中磷霉素浓度较高。
J Antimicrob Chemother. 2009 Sep;64(3):574-8. doi: 10.1093/jac/dkp230. Epub 2009 Jul 3.
4
Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.氨基糖苷类药物与磷霉素对铜绿假单胞菌的体外协同作用及大鼠模型生物膜感染研究
J Antimicrob Chemother. 2009 Sep;64(3):563-6. doi: 10.1093/jac/dkp224. Epub 2009 Jun 26.
5
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.NXL104与β-内酰胺类药物联合对产KPC碳青霉烯酶的肺炎克雷伯菌分离株的体外活性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3599-601. doi: 10.1128/AAC.00641-09. Epub 2009 Jun 15.
6
Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature.泛耐药肺炎克雷伯菌感染：2例报告及文献简要综述
Clin Infect Dis. 2009 Jul 15;49(2):271-4. doi: 10.1086/600042.
7
Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece.产KPC-2碳青霉烯酶肺炎克雷伯菌菌株在希腊的克隆传播。
J Antimicrob Chemother. 2009 Aug;64(2):348-52. doi: 10.1093/jac/dkp207. Epub 2009 Jun 13.
8
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.美国产KPC肺炎克雷伯菌分离株的分子流行病学：多位点序列类型258的克隆扩增
Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70. doi: 10.1128/AAC.00126-09. Epub 2009 Jun 8.
9
The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.ARESC研究：一项关于单纯性尿路感染相关病原体抗菌药物耐药性的国际调查。
Int J Antimicrob Agents. 2009 Nov;34(5):407-13. doi: 10.1016/j.ijantimicag.2009.04.012. Epub 2009 Jun 7.
10
Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.磷霉素用于治疗多重耐药非发酵革兰氏阴性杆菌引起的感染：微生物学、动物和临床研究的系统评价
Int J Antimicrob Agents. 2009 Aug;34(2):111-20. doi: 10.1016/j.ijantimicag.2009.03.009. Epub 2009 Apr 28.
Zotero 插件